Steroidogenic acute regulatory protein-related lipid transfer

Merck & Co., Inc., Kenilworth, NJ, USA is a global healthcare leader working to help the world be well. From developing new therapies that treat and prevent disease to helping people in need, we are committed to improving health and well-being around the world.  The Merck Manual was first published in 1899 as a service to the community.  The legacy of this great resource continues as the Merck Manual in the US and Canada and the MSD Manual outside of North America.   Learn more about our commitment to Global Medical Knowledge.

Diagnosis Index entries containing back-references to :

  • Abnormal, abnormality, abnormalities - see also Anomaly
    • chromosome, chromosomal ICD-10-CM Diagnosis Code Chromosomal abnormality, unspecified
        2016 2017 2018 Billable/Specific Code POA Exempt
      • sex
      • specified NEC
  • Additional - see also Accessory
    • chromosome (s)
  • Anomaly, anomalous (congenital) (unspecified type) ICD-10-CM Diagnosis Code Congenital malformation, unspecified
      2016 2017 2018 Billable/Specific Code POA Exempt
    Applicable To
    • Congenital anomaly NOS
    • Congenital deformity NOS
    • chromosomes, chromosomal ICD-10-CM Diagnosis Code Chromosomal abnormality, unspecified
        2016 2017 2018 Billable/Specific Code POA Exempt
      • specified NEC
  • Syndrome - see also Disease
    • due to abnormality
      • chromosomal ICD-10-CM Diagnosis Code Chromosomal abnormality, unspecified
          2016 2017 2018 Billable/Specific Code POA Exempt
        • specified NEC
  • Translocation
    • chromosomes NEC

The mechanism is unknown, but the trypanocidal activity may be due to the inhibition of enzymes involved with the oxidation of reduced nicotinamide-adenine dinucleotide (NADH), which functions as a co-enzyme in many cellular reactions, such as respiration and glycolysis, in the trypanosome parasite. Suramin's action in the treatment of onchocerciasis is macrofilaricidal and partially microfilaricidal. It may also act as an antagonist of P2 receptors and as an agonist of Ryanodine receptors. It also can inhibit follicle-stimulating hormone receptors.

One study has been conducted in athletes given D-aspartic acid supplementation at a dose of 3g daily for 28 days, and there was a failure to increase testosterone concentrations when measured at 28 days. [32] This study noted a statistically significant induction of serum D-aspartate oxidase (DAO) which degrades D-aspartate [53] to a near doubling; [32] this suggests a possible form of negative feedback, and aromatase (may also be induced by D-aspartic acid [24] ) was not thought to contribute due to estrogen being unchanged.

Steroidogenic acute regulatory protein-related lipid transfer

steroidogenic acute regulatory protein-related lipid transfer

One study has been conducted in athletes given D-aspartic acid supplementation at a dose of 3g daily for 28 days, and there was a failure to increase testosterone concentrations when measured at 28 days. [32] This study noted a statistically significant induction of serum D-aspartate oxidase (DAO) which degrades D-aspartate [53] to a near doubling; [32] this suggests a possible form of negative feedback, and aromatase (may also be induced by D-aspartic acid [24] ) was not thought to contribute due to estrogen being unchanged.

Media:

steroidogenic acute regulatory protein-related lipid transfersteroidogenic acute regulatory protein-related lipid transfersteroidogenic acute regulatory protein-related lipid transfersteroidogenic acute regulatory protein-related lipid transfersteroidogenic acute regulatory protein-related lipid transfer

http://buy-steroids.org